Please select the option that best describes you:
What adjuvant therapy would you offer a postmenopausal woman with a new pT2N0 HR+/HER2+ breast cancer primary who is concurrently being treated with anastrozole/ribociclib for well controlled oligometastatic HR+/HER2- disease?
The new primary was incidentally picked up on re-staging scans for the metastatic ER+ cancer. Would you modify the CDK4/6i and AI? What HER2 therapy would you offer?
Answer from: Medical Oncologist at Academic Institution
It is always disconcerting when a primary tumor arises in the context of already ongoing therapy. Presumably, this tumor is somewhat resistant. Firstly, I would add in anti-HER2 therapy (there is a broad range of options depending on the patient's details, ranging from single-agent trastuzumab to TH...
Sign In or Register to read more